Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2026-01-12 Regulatory Filings
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing the renewal of a Marketing Authorization (MA) for a pharmaceutical product (Sibnayal) by the European Medicines Agency. It does not report financial results, board changes, or shareholder voting, nor is it a formal regulatory filing or a report publication announcement. As it is a general corporate announcement regarding business operations and regulatory milestones, it falls under the 'Regulatory Filings' (RNS) category as the best fit for miscellaneous corporate news.
2026-01-12 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release issued by Advicenne announcing the successful renewal of the marketing authorization (AMM) for their drug Sibnayal in the European Union. It is a short, news-oriented announcement (under 5,000 characters) regarding a regulatory milestone. Since it does not fit into specific categories like financial reports, dividends, or board changes, and serves as a general corporate regulatory announcement, it is classified as a Regulatory Filing (RNS).
2026-01-12 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Advicenne announcing the filing of a registration dossier for their drug Sibnayal® with the US FDA. It is a corporate announcement regarding regulatory progress and business development, not a financial report, audit, or proxy statement. Since it does not fit into specific categories like M&A or dividend announcements, and serves as a general corporate regulatory update, it is classified as a Regulatory Filing (RNS).
2025-11-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing a regulatory milestone (submission of a registration application to the US FDA for a drug). It does not fit into specific categories like financial reports, dividend announcements, or director dealings. As it is a general corporate announcement regarding business operations and regulatory progress, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-11-04 English
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 1% confidence The document is a press release titled 'Advicenne reports First Half financial results as of June 30, 2025'. It contains detailed financial tables (income statement, cash flow highlights) and management commentary regarding the company's performance for the first half of the fiscal year. While it mentions that the full financial report is available on the website, the document itself provides substantive financial data and analysis for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than just a publication announcement. H1 2025
2025-09-19 English
Informations privilégiées / Communiqué sur comptes, résultats
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the six-month period ending June 30, 2025. It includes detailed financial statements (income statement, cash flow context), management's analysis of financial results, business trends, and outlook. It is not merely an announcement of a report, as it contains substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report (IR). H1 2025
2025-09-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.